Product Description
for Adults With Attention Deficit Hyperactivity Disorder (ADHD) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02257216)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Enzymotec
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02222285 |
Vayarin_005 | N/A |
Completed |
Autism Spectrum Disorder |
2017-05-01 |
2019-03-20 |